A randomized, double-blind, split-face study of topical silymarin versus 2% hydroquinone cream in melasma
- Conditions
- MelasmaMelasma, Silymarin, Hydroquinone, Silibinin
- Registration Number
- TCTR20210729003
- Lead Sponsor
- /A
- Brief Summary
After treatment, both sides showed significant improvement of RL*I. Mean improvement rates of RL*I were 14.56% (SD 43.09) and 12.82 % (SD 38.19) for silymarin and hydroquinone respectively. Modified MASI score decreased after both treatments but was only significant on the hydroquinone side after the first month of treatment (% reduction of modified MASI 17.98%, P 0.019). However, there were no statistically significant differences in the RL*I and modified MASI between the two treatments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 23
25 female patients with epidermal or mixed-type melasma on both cheeks
1.Patients with pregnancy and lactation
2. Received hormonal therapy or contraceptive pills within 1 year
3. Received any topical treatment within 1 month
4. Received laser treatment within 3 months
5. Having other facial dermatologic conditions or present of any life-threatening underlying diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of melasma 12 weeks modified MASI score, relative lightness index,Patient-self assessment 12 weeks VAS
- Secondary Outcome Measures
Name Time Method Adverse effects 12 weeks All occurring adverse effects of silymarin and hydroquinone were recorded at each visit